Clinical Trial: NCT04953104
ARID1A and/or KDM6A Mutation and CXCL13 Expression
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | M.D. Anderson Cancer Center |
| Information Provided By: | M.D. Anderson Cancer Center |
| Last Update Posted: | 2026-10-06 |
Study Overview
Brief Summary
This phase II trial studies the effect of nivolumab in urothelial cancer that has spread to other places in the body (metastatic), specifically in patients with aberrations in ARID1A gene (ARID1A mutation) and correlate with expression level of CXCL13, an immune cytokine. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab may help control the disease in patients with urothelial cancer or solid tumors. This trial aims at enriching patient selection based on genomic and immunological attributes of the tumor.
Official Title
Conditions
Intervention / Treatment
- Other: Diagnostic Laboratory Biomarker Analysis
- Biological: Nivolumab
- Drug: Relatlimab
Other Study ID Numbers
- 2021-0104
- NCI-2021-05785
- 2021-0104
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | M.D. Anderson Cancer Center |
| Information Provided By: | M.D. Anderson Cancer Center |
| Last Update Posted: | 2026-10-06 |
Study Overview
Brief Summary
This phase II trial studies the effect of nivolumab in urothelial cancer that has spread to other places in the body (metastatic), specifically in patients with aberrations in ARID1A gene (ARID1A mutation) and correlate with expression level of CXCL13, an immune cytokine. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab may help control the disease in patients with urothelial cancer or solid tumors. This trial aims at enriching patient selection based on genomic and immunological attributes of the tumor.
Official Title
Conditions
Intervention / Treatment
- Other: Diagnostic Laboratory Biomarker Analysis
- Biological: Nivolumab
- Drug: Relatlimab
Other Study ID Numbers
- 2021-0104
- NCI-2021-05785
- 2021-0104